Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 30];9(6):s692. Available from: https://skin.dermsquared.com/skin/article/view/3778